The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
about
Proteolytic Processing of ErbB4 in Breast CancerHigh Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to PaclitaxelThe ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epitheliumThe localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistanceLandscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locationsQuantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein.Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor familyActivated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyExpression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic RegulationSubcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors.Potential of ErbB4 antibodies for cancer therapy.WWOX gene and gene product: tumor suppression through specific protein interactions.Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer.A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression
P2860
Q27670640-134721CF-1196-4712-896A-92A7B366F670Q28548522-910D7E7C-856D-4A9C-8109-F6CF1A4BA3BBQ33951695-21D6D22E-DF20-4872-8C21-FE240429BB58Q33977133-8F2FC4A2-BA8E-4E52-A6F8-AF2F8072407EQ33998459-DEB064F2-A475-4CD8-BE28-046F52CE034DQ34363866-FA9C49D1-4C89-450C-BC48-5E8F7C2D9D75Q34428718-40180114-907F-492B-99AE-7A61870D62A5Q34506613-7883E450-5FEE-43C7-B79E-02417FEBB417Q34756694-F79F8D05-000D-446B-A921-446F610E34BCQ35831012-F71C1D92-3A22-4518-B0D2-9771CB6C3558Q35888647-5A8B8A81-96D1-4E5F-BC33-AFA0F24E9494Q36080448-6A450E16-45B8-4F58-8ECC-9D1ACEC8E581Q36113481-AE2F5D5C-82FF-44F4-A460-519C8A1128AFQ36162605-F703B260-E25B-4313-95A0-283B3FF452BDQ36223407-0CE0E6EB-C344-43F5-A9DA-EFEC15E9BF7EQ37141830-FCDD8A26-5FD3-46A2-9B8B-4350DB29E978Q37413628-91AEA408-EC04-482B-847F-148F63FE64E6Q37622619-F5616AA4-69F2-485F-94B1-BD510F7F1D88Q37658764-61DBE782-4886-4C00-9586-13B497B5DFB6Q37690302-0F565FD9-FDB2-4E73-B8F7-E8CEF3F9CEB4Q37718269-407E2030-464F-47F9-B3F7-4E184584A754Q37727542-CF5D0F15-BCA2-4730-B538-6E65F21E685BQ39028181-E4C6163A-FCE8-4D30-8C92-5E3BDF4EC855Q39044090-C4FACA55-17FA-431F-B817-8B3DA058EE2FQ39098404-A09808F4-6A25-41D8-AC00-C073147C85D2Q39579728-C87D87FA-763E-47CD-9275-C458D1F187F3Q44811677-AA750344-40E6-45C1-A6FA-0EDEDF800529Q54286036-0001A0EA-080F-4A07-B267-966A230AA2A0Q56968081-85C39049-4AAF-4355-95B6-C725FC2311EE
P2860
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The HER4/4ICD estrogen recepto ...... f tamoxifen-induced apoptosis.
@en
type
label
The HER4/4ICD estrogen recepto ...... f tamoxifen-induced apoptosis.
@en
prefLabel
The HER4/4ICD estrogen recepto ...... f tamoxifen-induced apoptosis.
@en
P2093
P2860
P1433
P1476
The HER4/4ICD estrogen recepto ...... f tamoxifen-induced apoptosis.
@en
P2093
Anjali Naresh
Ann D Thor
Frank E Jones
Kathleen C Torkko
Rakesh Kumar
Susan M Edgerton
P2860
P304
P356
10.1158/0008-5472.CAN-08-0538
P407
P577
2008-08-01T00:00:00Z